Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873278 | 0.94 | GRIN1 (0.37) | MAPK14GAACYP11B2ALDH1A1DHODH | |
| SCHEMBL4866909 | 0.92 | ALOX5AP (0.35) | CYP11B2MDM4MDM2ALOX5APRIPK3 | |
| SCHEMBL4875185 | 0.90 | PPARG (0.40) | MAOAMAOBALDH1A1ALOX5APKDM4E | |
| SCHEMBL4872023 | 0.88 | CYP17A1 (0.36) | ALDH1A1DHODHKDM4ERIPK3 | |
| SCHEMBL4868096 | 0.88 | KDM4E (0.39) | GAAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4867600 | 0.87 | DHODH (0.38) | ALDH1A1DHODHMEN1KMT2A | |
| SCHEMBL4878284 | 0.87 | MAOA (0.40) | GAAMAOAMAOBALDH1A1DHODH | |
| SCHEMBL4877209 | 0.86 | KDM4E (0.37) | ALDH1A1ALOX5APKDM4EMEN1KMT2A | |
| SCHEMBL4878878 | 0.86 | LMNA (0.40) | ALDH1A1ALOX5APKDM4EKMT2A | |
| SCHEMBL4872488 | 0.86 | KCNH2 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | MAPK14 3068/4885GAA 66/4885MAOA 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.